References of "Ruggeri, A"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOccurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.
Baron, Frédéric ULiege; Ruggeri, A.; Beohou, E. et al

in Journal of Internal Medicine (2018)

BACKGROUND: The efficacy of umbilical cord blood transplantation (UCBT) as treatment for acute myeloid leukaemia (AML) relies on immune-mediated graft-versus-leukaemia effects. Previous studies have ... [more ▼]

BACKGROUND: The efficacy of umbilical cord blood transplantation (UCBT) as treatment for acute myeloid leukaemia (AML) relies on immune-mediated graft-versus-leukaemia effects. Previous studies have suggested a strong association between graft-versus-host disease (GVHD) occurrence and graft-versus-leukaemia effects after allogeneic hematopoietic cell transplantation. METHODS: Here, we evaluated the kinetics of relapse rate in correlation with GVHD occurrence after UCBT. The kinetics of relapse rate over time in correlation to GVHD occurrence were assessed by calculating the relapse rate per patient-year within sequential 90-day intervals. The impact of GVHD on relapse and mortality was further studied in multivariate Cox models handling GVHD as a time-dependent covariate. RESULTS: The study included data from 1068 patients given single (n = 567) or double (n = 501) UCBT. The proportion of patients with grade II, III and IV acute GVHD was 20%, 7% and 4%, respectively. At 2 years, the cumulative incidence of chronic GVHD was 42%, the cumulative incidence of relapse was 32%, and overall survival was 32% as well. Relapse rates declined gradually over time during the first 30 months after transplantation. There was a possible suggestion that grade II-IV acute (HR = 0.8, P = 0.1) and chronic (HR = 0.65, P = 0.1) GVHD decreased relapse risk. However, grade II-IV acute GVHD significantly increased early (the first 18 months after UCBT) mortality (HR = 1.3, P = 0.02), whilst chronic GVHD increased each early (HR = 2.7, P < 0.001) and late (HR = 4.9, P < 0.001) mortality after UCBT. CONCLUSIONS: The occurrence of grade II-IV acute or chronic GVHD each increases overall mortality after UCBT for AML mitigating the possible graft-versus-leukemia effect of GVHD. [less ▲]

Detailed reference viewed: 45 (1 ULiège)
Full Text
Peer Reviewed
See detailAllogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT
Roth-Guepin, G.; Canaani, J.; Ruggeri, A. et al

in Oncotarget (2017), 8(68), 112972-112979

Hematopoietic stem cell transplantation (HSCT) is being increasingly explored as a treatment modality for older patients with acute lymphoblastic leukemia (ALL). Yet, concerns regarding the long term ... [more ▼]

Hematopoietic stem cell transplantation (HSCT) is being increasingly explored as a treatment modality for older patients with acute lymphoblastic leukemia (ALL). Yet, concerns regarding the long term outcome of transplantation in older patients limit the wide spread applicability of this approach. In this analysis we set out to determine the outcome of ALL patients over the age of 60 who underwent reduced intensity HSCT. Herein, we present the experience of the acute leukemia working party (ALWP) of the EBMT in this age group. We analyzed a cohort of 142 patients transplanted in first remission with a median age of 62 (range 60-76 years) and a median follow-up period of 36 months post-transplant. At 3 years, overall survival (OS) and leukemia-free survival were 42% and 35%, respectively. Multivariate analyses identified cytomegalovirus (CMV) donor-recipient matching (CMV D+/R+) to be significantly associated with inferior OS. Patients transplanted from unrelated donors experienced increased grade II-IV acute graft versus host disease compared to those receiving grafts from matched related donors [Hazard ratio (HR) of 3.7, 95% confidence interval (CI), 1.75-7.8; p = 0.0005). Outcome was not impacted by Philadelphia chromosome status. A select subset of older ALL patients will benefit from extended survival and a disease free state following HSCT. © Roth-Guepin et al. [less ▲]

Detailed reference viewed: 12 (0 ULiège)
Full Text
Peer Reviewed
See detailOutcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, eurocord and EBMT collaborative analysis.
Ustun, C.; Giannotti, F.; Zhang, M.-J. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2017)

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FLT3+ acute myeloid leukemia (AML ... [more ▼]

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FLT3+ acute myeloid leukemia (AML) that has poor prognosis due to high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126), (HR 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically not significant 3-year LFS: 39% (95% CI 30-47) after UCB, 43% (95% CI 30-54) after sibling, and 50% (95% CI 40-60) after URD. Chronic GVHD rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2. UCB is a suitable option for adults with FLT3+AML in the absence of an HLA-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common thus allowing HCT in CR1 when outcomes are best.Leukemia accepted article preview online, 25 January 2017. doi:10.1038/leu.2017.42. [less ▲]

Detailed reference viewed: 26 (0 ULiège)
Full Text
Peer Reviewed
See detailMethods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications
Baron, Frédéric ULiege; Ruggeri, A.; Nagler, A.

in Expert Review of Hematology (2016), 21

More than 40,000 unrelated cord blood transplantations (UCBT) have been performed worldwide as treatment for patients with malignant or non-malignant life threatening hematologic disorders. However, low ... [more ▼]

More than 40,000 unrelated cord blood transplantations (UCBT) have been performed worldwide as treatment for patients with malignant or non-malignant life threatening hematologic disorders. However, low absolute numbers of hematopoietic stem and progenitor cells (HSPCs) within a single cord blood unit has remained a limiting factor for this transplantation modality, particularly in adult recipients. Further, because UCB contains low numbers of mostly naïve T cells, immune recovery after UCBT is slow predisposing patients to severe infections. Other causes of UCBT failure has included graft-versus-host disease (GVHD), and relapse of the underlying disease. In this article, we first review the current landscape of cord blood engineering aimed at improving engraftment. This includes approaches of UCB-HSPCs expansion and methods aimed at improving UCB-HSCPs homing. We then discuss recent approaches of cord blood engineering developed to prevent infection (generation of multivirus-specific cytotoxic T cells (VSTs) from UCB), relapse (transduction of UCB-T cells with tumor-specific chimeric receptor antigens (CARs)) and GVHD (expansion of regulatory T cells from UCB). Although many of these techniques of UCB engineering remain currently technically challenging and expensive, they are likely to revolutionize the field of UCBT in the next decades. [less ▲]

Detailed reference viewed: 17 (2 ULiège)
Full Text
Peer Reviewed
See detailModification of standard ISHAGE methodology for CD34+ cells count on thawed Cord Blood Units: results from a multi-center Eurocord/Netcord study
Saccardi, RICCARDO; Azqueta, C; Ballerini, C et al

in Bone Marrow Transplantation (2015), 50

Detailed reference viewed: 64 (4 ULiège)
Full Text
Peer Reviewed
See detailEffect of volume reduction of cord blood units before storage on transplantation outcomes: a retrospective analysis of Eurocord-EBMT and Netcord
SACCARDI, R; Tucunduva, L; Ruggeri, A et al

in Bone Marrow Transplantation (2013, April 01), 48

In this Registry study, manipulation of the CBUs aimed at volume reduction was not shown to infl uence the clinical outcome, indicating a satisfactory validation of the associated technologies across the ... [more ▼]

In this Registry study, manipulation of the CBUs aimed at volume reduction was not shown to infl uence the clinical outcome, indicating a satisfactory validation of the associated technologies across the banks. Cells viability assessment methodology varied among banks. Further eff orts to standardize the quality controls before CBU release are needed. [less ▲]

Detailed reference viewed: 15 (3 ULiège)
Full Text
Peer Reviewed
See detailEffect of HLA-matching recipients to donor non-inherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy
Rocha, V; Spellman, S; Zhang, MJ et al

in Biology of Blood & Marrow Transplantation (2012)

Detailed reference viewed: 29 (5 ULiège)
Peer Reviewed
See detailEvidence for basement membranes in rat tail tendon sheaths.
Guizzardi, S.; Foidart, Jean-Michel ULiege; Leonardi, L. et al

in Basic and Applied Histochemistry (1987), 31(2), 177-81

The presence of anti-laminin antibodies and a basement membrane-like thin electrondense lamina has been demonstrated in the peritendineum of the rat tail tendon by indirect immunofluorescence and electron ... [more ▼]

The presence of anti-laminin antibodies and a basement membrane-like thin electrondense lamina has been demonstrated in the peritendineum of the rat tail tendon by indirect immunofluorescence and electron microscopy. [less ▲]

Detailed reference viewed: 11 (0 ULiège)